UPDATE: Piper Jaffray Initiates Coverage On Aratana Therapeutics Inc On Approaching Catalysts

In a report published Tuesday, Piper Jaffray analyst Kevin K. Ellich initiated coverage on Aratana Therapeutics Inc PETX with an Overweight rating and $17.00 price target. In the report, Piper Jaffray noted, “We are initiating coverage of Aratana Therapeutics with an Overweight rating and $17 PT. PETX is the leader in the emerging pet therapeutic industry with the deepest pipeline and a very experienced management team. While the recent equity offering removed an overhang on the stock, in our view, there are a number of upcoming catalysts that could push shares higher, including 1) USDA approval for its B-cell lymphoma monoclonal antibody product (AT-004), 2) positive top-line results for its pain and inflammation product (AT-001), and 3) a positive, limited rollout for its T-cell lymphoma product (AT-005) to a couple dozen animal hospitals.” Aratana Therapeutics Inc closed on Monday at $10.62.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsKevin K. EllichPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!